This research focused on formulating finasteride, dutasteride, and minoxidil with cyclodextrins to enhance their solubility and skin penetration for topical use, potentially reducing scalp irritation from current alcohol-based preparations.
In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
October 2023 in “Revista Medicina Cutánea Ibero-Latino-Americana” In a study conducted on 257 Latin American patients with alopecia areata, researchers found that the most frequent lesion location was the scalp, affecting 86.1% of participants, and reported multiple associated comorbidities, notably cardiovascular and endocrine diseases, with certain conditions being more common in women.
123 citations
,
January 2020 in “International Journal of Molecular Sciences” This review discusses the role of fibroblast heterogeneity in determining skin scarring versus regeneration and reports no new results, highlighting opportunities for developing antiscarring therapies.